Memorial Sloan-Kettering Cancer Center
Demonstrated how genetic and therapeutic inhibition of the cyclin D1-CDK4 kinase impacts glioma formation and maturation of the tumor microenvironment, an essential step for applying CDK inhibitors clinically.
* Led multi-disciplinary research team assessing therapeutic inhibition of CDK4 for treatment of glioma.* Validated the novel role of cyclin D1 and CDK4 in PDGF-mediated glioma using state-of-the-art RCAS-tvA
mouse system for somatic gene transfer.* Developed protocol for isolation of primary microglial (immune) cells from murine cortices.* Generated in vitro cell line surrogates to study the role of cyclin D1 and CDK4 in glioma.* Core organizer of the institutional postdoctoral symposium (new format still in use today).* Speaker (invited) for numerous seminars and panels on effective presentation skills.* Supervised 3 graduate/summer research students.* Executed immunofluorescence and flow-based assays to identify a function for cyclin D1 and CDK4 in
glioma and microglial cell biology.